TMPRSS2 and metastatic neoplasm: Among different HSD3B1 c.1100 genotypes, we did not find differences in the prevalence of AR, FOXA1, or SPOP alterations, AR-V7 expression, or TMPRSS2-ERG fusions across HSD3B1 genotypes in both primary and metastatic tumors (Figure 2A,B).